重组蛋白
Search documents
同花顺果指数概念涨4.17%,主力资金净流入这些股
Zheng Quan Shi Bao Wang· 2025-05-12 10:04
Concept Performance - The top-performing concept sectors today include China Shipbuilding System with a gain of 6.55%, Chengfei Concept at 5.77%, and Military Information Technology at 4.28% [1] - Conversely, the underperforming sectors include Recombinant Protein down by 0.94%, Sugar Substitute down by 0.82%, and Transgenic down by 0.77% [1] Capital Inflow - The Tonghuashun Fruit Index concept sector saw a net inflow of 2.447 billion yuan, with 18 stocks experiencing net inflows and 8 stocks exceeding 100 million yuan in net inflow [1] - Leading the net inflow is Luxshare Precision with 836 million yuan, followed by Dongshan Precision, GoerTek, and Lens Technology with net inflows of 266 million yuan, 254 million yuan, and 201 million yuan respectively [1] Stock Performance - As of May 12, the Tonghuashun Fruit Index concept rose by 4.17%, ranking fourth among concept sectors, with 20 stocks increasing in value [3] - Notable gainers include Lens Technology at 9.63%, Changying Precision at 7.04%, and Luxshare Precision at 6.36% [3] Capital Inflow Ratios - Leading the capital inflow ratios are Lingyi iTech, Dongshan Precision, and Pengding Holdings with net inflow rates of 12.28%, 10.69%, and 10.53% respectively [2][4] - The detailed capital inflow data shows that Luxshare Precision had a turnover rate of 3.80% with a net inflow ratio of 9.08% [2]
重组蛋白概念下跌0.94%,主力资金净流出27股
Zheng Quan Shi Bao Wang· 2025-05-12 08:39
截至5月12日收盘,重组蛋白概念下跌0.94%,位居概念板块跌幅榜前列,板块内,迈威生物、泽璟制 药、阿拉丁等跌幅居前,股价上涨的有16只,涨幅居前的有*ST万方、百普赛斯、*ST苏吴等,分别上 涨2.73%、2.69%、2.58%。 今日涨跌幅居前的概念板块 | 代码 | 简称 | 今日涨跌幅(%) | 今日换手率(%) | 主力资金流量(万元) | | --- | --- | --- | --- | --- | | 688166 | 博瑞医药 | -3.34 | 3.24 | -9247.96 | | 688266 | 泽璟制药 | -7.80 | 2.14 | -5042.00 | | 300723 | 一品红 | -1.36 | 2.96 | -4614.17 | | 002584 | 西陇科学 | 0.56 | 10.62 | -2062.55 | | 688136 | 科兴制药 | -2.77 | 1.52 | -1992.98 | | 688068 | 热景生物 | -5.39 | 4.08 | -1842.96 | | 600223 | 福瑞达 | -1.08 | 1.40 | -1498.6 ...
重组蛋白概念下跌1.56%,5股主力资金净流出超千万元
Zheng Quan Shi Bao Wang· 2025-04-25 09:38
Market Performance - The recombinant protein sector declined by 1.56%, ranking among the top losers in concept sectors as of April 25 [1][2] - Notable stocks within the sector that hit the daily limit down include Jiangsu Wuzhong and Weiming Pharmaceutical, while stocks like HJ Bio, Wanfang Development, and Aladdin saw significant declines [1] Top Gainers and Losers - Among the top gainers in the recombinant protein sector, Borui Pharmaceutical, BeiDa Pharmaceutical, and Tonghua Dongbao increased by 4.39%, 2.42%, and 2.31% respectively [1] - The sector experienced a net outflow of 158 million yuan, with 22 stocks seeing net outflows, and five stocks exceeding 10 million yuan in outflows [2] Capital Flow Analysis - The stock with the highest net outflow was Xilong Science, with a net outflow of 190 million yuan, followed by Furida and Dezhan Health with outflows of 19.41 million yuan and 19.18 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflows included Zhongyuan Qihua, Zhifei Biological, and Chengdu Xian Dao, with inflows of 26.63 million yuan, 25.06 million yuan, and 17.51 million yuan respectively [2][3]
重组蛋白概念上涨2.32%,6股主力资金净流入超千万元
Zheng Quan Shi Bao Wang· 2025-03-27 09:13
Group 1 - The recombinant protein concept sector rose by 2.32%, ranking fifth among concept sectors, with 40 stocks increasing in value [1] - Notable gainers in the sector included Xilong Science, which hit the daily limit, and other companies like Maiwei Biotech, Hotgen Biotech, and Zexin Pharmaceutical, which rose by 11.05%, 8.16%, and 7.91% respectively [1] - The sector experienced a net inflow of 354 million yuan from main funds, with 23 stocks receiving net inflows, and six stocks exceeding 10 million yuan in net inflow [2] Group 2 - The top stocks by net inflow included Xilong Science with 282 million yuan, followed by Huabei Pharmaceutical, Borui Pharmaceutical, and Maiwei Biotech with net inflows of 29.71 million yuan, 27.06 million yuan, and 14.97 million yuan respectively [2][3] - Xilong Science led the sector with a net inflow rate of 30.58%, followed by Innotec and Kexing Pharmaceutical with rates of 13.12% and 11.83% respectively [3] - The overall performance of the recombinant protein sector reflects strong investor interest and capital flow, indicating potential growth opportunities within this industry [2][3]